Core Viewpoint - The A-share market has shown a strong performance, with the Shanghai Composite Index reaching 3700 points, indicating a recovery from previous economic shocks. A trend of gradual growth has emerged since April 27, following the impact of U.S. tariffs, leading to a widening gap between stock strategies and other primary strategies [1]. Summary by Categories Market Performance - The A-share market has entered a four-month trend of gradual growth, with a noticeable recovery in the index [1]. - Quantitative long strategies and subjective long strategies have both performed well, with quantitative long strategies achieving a return of 25.02% and subjective long strategies averaging 5.86% in July [3][4]. Strategy Performance - Among various strategies, subjective long strategies have outperformed quantitative long strategies due to their concentrated positions and flexibility in trading [4]. - The average return for subjective long strategies across different scales of private equity funds has been significant, with the highest returns observed in the 10-20 billion category at 25.43% [18]. Fund Performance - The top-performing subjective long products in the 100 billion category include "和谐汇一医疗创新B类份额" managed by 施跃, achieving a return of ***% [7][5]. - In the 50-100 billion category, "同犇22期" managed by 童驯 led with a return of ***% [14]. - The 20-50 billion category saw "丹羿鹏程1号1期" managed by 王帅 achieving a return of ***% [17]. - In the 10-20 billion category, "能敬价值优选二号" managed by 孙杰 led with a return of ***% [21]. - The 5-10 billion category was topped by "优波三号A类份额" managed by 陈龙 with a return of ***% [24]. - The 0-5 billion category saw "子衿云杉" managed by 邹凯 achieving a return of ***% [28]. Investment Insights - Fund managers are focusing on sectors such as innovative pharmaceuticals and medical devices, indicating a re-evaluation of high-quality assets in China [8]. - The market is currently in a phase where investors are cautious about the sustainability of earnings for companies that have seen significant price increases [8].

Core Viewpoint - The pharmaceutical industry has experienced a significant rebound in 2023 after years of policy adjustments and market corrections, with a year-to-date increase of 37.42%, leading all sectors in performance [1]. Group 1: Investment Performance - The "Harmonious Huiyi Medical Innovation B Class" fund, managed by Harmony Huiyi's investment manager Shi Yue, was established during a downturn in the pharmaceutical sector and has achieved impressive returns since its inception [2]. - The fund's performance includes a significant return since its establishment on August 16, 2022, and a notable increase in 2023 [2]. Group 2: Manager Insights - Shi Yue, with 15 years of experience in the securities industry, emphasizes the pharmaceutical sector's resilience driven by demographic trends and healthcare needs [3][6]. - The investment strategy focuses on long-term investments in high-growth companies within the pharmaceutical sector, with a preference for companies in the growth and early maturity phases [6][10]. Group 3: Market Trends and Future Outlook - The pharmaceutical sector is characterized by its weak cyclicality and low correlation with macroeconomic factors, making it a stable investment choice [6]. - The current market dynamics show a strong focus on innovative drugs and medical devices, with a positive outlook for the sector's performance in the coming years [11][15]. - The recent rebound in the pharmaceutical sector is attributed to a re-evaluation of high-quality assets in China, with a focus on innovative drugs and medical devices [10][11]. Group 4: Investment Strategy - The investment approach involves a top-down selection of high-growth sub-industries and a focus on companies with strong growth potential [6][10]. - Shi Yue's strategy includes a global perspective, utilizing flexible allocation across A-shares, Hong Kong stocks, and U.S. stocks to capture diverse alpha opportunities [9][10]. - The emphasis is on identifying high-value, high-frequency consumption products within the pharmaceutical sector, particularly in oncology [12].

Market Performance - In the first half of 2025, the A-share market showed strong resilience amid a complex domestic and international environment, with the Shanghai Composite Index rising by 2.75% and the North Stock 50 Index leading with a remarkable increase of 39.45% [1] - The total trading volume in the A-share market reached 162.68 trillion yuan, significantly higher than the 101 trillion yuan recorded in the same period of 2024, indicating a rapid increase in market activity [1] Private Equity Fund Performance - Among the 495 billion private equity products with reported performance, the average return for the first half of the year was 10.18%, with an excess return of 8.84% [2] - There was a notable divergence in performance among different strategies, with quantitative long strategies achieving an average return of 18.84%, while subjective long strategies only averaged 3.32% [1][2] Strategy Breakdown Quantitative Long Strategies - A total of 194 quantitative long products were reported, with the top performers identified based on excess returns [3] - The leading product was from Longqi Technology, with significant returns attributed to favorable market conditions and a strong belief in the potential for excess returns in the Chinese market [7][8] Subjective Long Strategies - There were 165 subjective long products, with the average return being only 3.32%, highlighting a stark contrast with quantitative strategies [4][11] - The top-performing product in this category focused on medical innovation, benefiting from strong market trends in the healthcare sector [11] Market Neutral Strategies - The average return for 35 market-neutral products was reported at 6.62%, with notable performers including Mingcong Investment and Weiguan Asset [12][14] Multi-Asset Strategies - The average return for 46 multi-asset strategies was 6.45%, with several products achieving significant returns [15][17] Futures and Derivatives Strategies - The average return for 25 futures and derivatives products was 3.82%, with the top product from Xinhong Tianhe showing strong performance [19][22]

Core Viewpoint - The A-share market demonstrated strong resilience in the first half of 2025, with a "volatile upward and structurally differentiated" trend, as evidenced by the performance of various indices and a significant increase in trading volume [2] Market Performance - The Shanghai Composite Index rose by 2.75%, the Shenzhen Component Index increased by 0.48%, and the ChiNext Index gained 0.53%. The North Stock 50 Index, representing small-cap stocks, saw the highest increase of 39.45% [2] - Total trading volume in the A-share market reached 162.68 trillion yuan, significantly higher than the 101 trillion yuan recorded in the same period of 2024, indicating a rapid increase in market activity [2] Private Equity Fund Performance - In the first half of 2025, 495 products from billion-yuan private equity firms reported performance, with an average return of 10.18% and an excess return of 8.84% [2][3] - There was a notable divergence in performance among different strategies, with quantitative long strategies achieving an average return of 18.84%, while subjective long strategies only averaged 3.32% [2][3] Strategy Breakdown Quantitative Long Strategies - A total of 194 quantitative long products were analyzed, with the top performers based on excess returns [4] - The top 10 quantitative long products included firms such as Longqi Technology and Stable Investment, with Longqi Technology's product leading the list [5][8] Subjective Long Strategies - There were 165 subjective long products, with an average return of 3.32%, indicating a significant performance gap compared to quantitative strategies [8] - The top performers in this category included Harmony One Asset and Evolutionary Asset, with a focus on sectors like medical innovation [12][9] Market Neutral Strategies - 35 market-neutral products were evaluated, with the top 10 showing an average return of ***% [13] - Notable firms in this category included Mingyuan Investment and Micro博易 [16] Multi-Asset Strategies - 46 multi-asset products were reviewed, achieving an average return of 6.45% [17] - The leading product in this category was from Blackwing Asset, which demonstrated strong performance [19] Futures and Derivatives Strategies - 25 products in the futures and derivatives category were analyzed, with an average return of 3.82% [20] - The top product was from Xinhong Tianhe, which achieved significant excess returns [23]